Skip to content

A Long Term Post-Marketing Study on the EffIcacy and Safety of Osmotic Release Oral System (OROS) Methylphenidate on the Cognitive Functions of Attention Deficit Hyperactivity Disorder (ADHD) Participants

An Open, Self-Controlled, Prospective Study of Concerta on Cognitive Functions, Efficacy and Tolerance in the Pediatric Patients With Attention Deficit Hyperactivity Disorder (ADHD)

Status
Completed
Phases
Phase 4
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT01933880
Enrollment
194
Registered
2013-09-02
Start date
2009-12-31
Completion date
2010-11-30
Last updated
2014-09-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Attention Deficit Hyperactivity Disorder (ADHD)

Keywords

Attention Deficit Hyperactivity Disorder, Methylphenidate Hydrochloride, CONCERTA

Brief summary

The purpose of this long term post-marketing study is to evaluate the effectiveness and safety of osmotic release oral system methylphenidate hydrochloride (OROS-MPH) in participants with Attention Deficit Hyperactivity Disorder (ADHD).

Detailed description

This is an open-label (all people know the identity of the intervention), prospective (study following participants forward in time), self-controlled, long-term post-marketing study in participants with ADHD. The study consists of 3 periods: screening period, wash-out period/run-in period (3 days), and open-label treatment period (12 weeks) which is divided into 2 periods that is dosage adjustment period and dose-optimization period. The total duration of the study is 12 weeks. During the dosage adjustment period, the dose of methylphenidate hydrochloride was adjusted to the optimal dose within 1-3 weeks starting with initial dosage of 18 milligram per day (mg/d) which can be increased to 36 mg/d up to a maximum dosage of 54 mg/d according to the therapeutic effect and tolerance or maintained at 36 mg or re-adjusted to 18 mg due to intolerance. Participants will receive the optimal dose determined during dose adjustment period for 9 weeks during the dose-optimization period. In the study, 2 types of participants will be enrolled in 2 groups (according to condition): OROS-MPH group (participants with ADHD) and the normal children group (healthy participants). The efficacy will be assessed primarily by Digit Span Test and Inattention /Over activity With Aggression (IOWA) Conners evaluation scale. Participants' safety will be monitored throughout the study.

Interventions

DRUGOsmotic Release Oral System Methylphenidate Hydrochloride (OROS-MPH)

Osmotic release oral system methylphenidate hydrochloride (OROS-MPH) starting at initial dosage of 18 milligram per day (mg/d) which can be increased to 36mg/d up to a maximum dosage of 54mg/d according to the therapeutic effect and tolerance or maintained at 36 mg or re-adjusted to 18mg due to intolerance.

OTHERNo intervention

Participants did not receive any study drug in this group. Participants were assessed for changes in the cognitive functions and the efficacy was compared with ADHD children.

Sponsors

Xian-Janssen Pharmaceutical Ltd.
Lead SponsorINDUSTRY

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
7 Years to 12 Years
Healthy volunteers
Yes

Inclusion criteria

* ADHD children must sign the consent form in person, and their parents or guardian must endorse, in the consent form, participation of the child in the designated research program * Through personal interaction and assessment questionnaire, examine to determine compliance of DSM-IV ADHD diagnostic criteria * According to the judgment of researchers, the ADHD children should have normal intelligence. Normal intelligence is defined as no obvious evidence of mental retardation in general (specific learning disabilities will not be considered mental retardation in general), formal IQ test to be conducted and 85 marks or above ought to be scored * ADHD children should not have been subjected to psychotropic drug treatment within 6 months. Those ADHD children on whom methylphenidate immediate-release tablets treatment is effective (with maximum daily dosage of 60 mg), may be admitted * Normal children with IQ greater than or equal to 85

Exclusion criteria

* Unable to fully comply with the cognitive function test in the laboratory * Known to be allergic to methylphenidate * Consumption of psychoactive drugs currently or in the past 30 days, including use of monoamine oxidase inhibitors, clonidine, other alpha 2 adrenergic receptor agonists, tricyclic antidepressants, theophylline, bishydroxycoumarin etc * History of alcohol, drugs or substances abuse * Have medical history of type I or II bipolar affective disorder, anxiety disorder, schizophrenia or pervasive developmental disorder

Design outcomes

Primary

MeasureTime frameDescription
Change From Baseline in Digit Span Test Total Score at Week 12Baseline and Week 12The digit span test is mainly used to measure the ability of short-term memory and attention. The participant will be given a string of digits and asked to repeat them forward, and then a second string of digits to repeat backward. The score is the number of correct responses, where the digits were repeated correctly. One point will be given for each correctly repeated string of digits. The maximum subscore in the Digits Forward is 16, and the maximum subscore in the Digits Backward is 14, summed for a total score of 30. A higher score is indicative of better recall and attention.
Change From Baseline in Inattention/Overactivity With Aggression (IOWA) Conners Behavior Rating Scale - I/O Score at Week 1Baseline and Week 1IOWA Conners Behavior Rating Scale evaluated by parents provides accurate measurement standards for behavioral change and therapeutic response. It includes 2 sub-scales: Inattention/Overactivity (I/O) subscale and Attacks (A), also known as Opposition/Defiant (O/D) sub-scale. IO (primary measurement ) will be assessed using 5-items and all Items will be scored on a 4-point scale (from 0=not at all to 3=very much). Total score range is from 0 to 15. Higher scores indicate worsening.
Change From Baseline in IOWA Conners Behavior Rating Scale - I/O Score at Week 2Baseline and Week 2IOWA Conners Behavior Rating Scale evaluated by parents provides accurate measurement standards for behavioral change and therapeutic response. It includes 2 sub-scales: Inattention/Overactivity (I/O) subscale and Attacks (A), also known as Opposition/Defiant (O/D) sub-scale. IO (primary measurement ) will be assessed using 5-items and all Items will be scored on a 4-point scale (from 0=not at all to 3=very much). Total score range is from 0 to 15. Higher scores indicate worsening.
Change From Baseline in IOWA Conners Behavior Rating Scale - I/O Score at Week 3Baseline and Week 3IOWA Conners Behavior Rating Scale evaluated by parents provides accurate measurement standards for behavioral change and therapeutic response. It includes 2 sub-scales: Inattention/Overactivity (I/O) subscale and Attacks (A), also known as Opposition/Defiant (O/D) sub-scale. IO (primary measurement ) will be assessed using 5-items and all Items will be scored on a 4-point scale (from 0=not at all to 3=very much). Total score range is from 0 to 15. Higher scores indicate worsening.
Change From Baseline in IOWA Conners Behavior Rating Scale - I/O Score at Week 7Baseline and Week 7IOWA Conners Behavior Rating Scale evaluated by parents provides accurate measurement standards for behavioral change and therapeutic response. It includes 2 sub-scales: Inattention/Overactivity (I/O) subscale and Attacks (A), also known as Opposition/Defiant (O/D) sub-scale. IO (primary measurement ) will be assessed using 5-items and all Items will be scored on a 4-point scale (from 0=not at all to 3=very much). Total score range is from 0 to 15. Higher scores indicate worsening.
Change From Baseline in IOWA Conners Behavior Rating Scale - I/O Score at Week 12Baseline and Week 12IOWA Conners Behavior Rating Scale evaluated by parents provides accurate measurement standards for behavioral change and therapeutic response. It includes 2 sub-scales: Inattention/Overactivity (I/O) subscale and Attacks (A), also known as Opposition/Defiant (O/D) sub-scale. IO (primary measurement ) will be assessed using 5-items and all Items will be scored on a 4-point scale (from 0=not at all to 3=very much). Total score range is from 0 to 15. Higher scores indicate worsening.

Secondary

MeasureTime frameDescription
WCST: Percentage of Correct Responses (Rc%)Baseline and End of Week 12WCST is used to evaluate participants' abilities of abstract generalization, working memory, and distraction-cognitive clinically, which reflects participants' cognitive function objectively and comprehensively. WCST consists of 13 test indicators and all indicators will be analyzed separately. The 13 indicators are as follows: number of trials administered; number of categories completed; response corrects; percent corrects; total number of errors; trials to complete first category; percent conceptual level responses; perseverative responses; perseverative errors; percent perseverative errors; nonperseverative errors; failure to maintain set; learning to learn. Percentage of correct responses which meets all the requirements according to the response principles was evaluated. Ranges from 0 to 100 percent (%), the more the better.
WCST: First Response (Rf)Baseline and End of Week 12WCST is used to evaluate participants' abilities of abstract generalization, working memory, and distraction-cognitive clinically, which reflects participants' cognitive function objectively and comprehensively. WCST consists of 13 test indicators and all indicators will be analyzed separately. The 13 indicators are as follows: number of trials administered; number of categories completed; response corrects; percent corrects; total number of errors; trials to complete first category; percent conceptual level responses; perseverative responses; perseverative errors; percent perseverative errors; nonperseverative errors; failure to maintain set; learning to learn. Number of responses needed to complete the first color classification was evaluated. Ranges from 9 to 128, the lesser the better.
WCST: Percentage of Conceptual Level Responses (Rf%)Baseline and End of Week 12WCST is used to evaluate participants' abilities of abstract generalization, working memory, and distraction-cognitive clinically, which reflects participants' cognitive function objectively and comprehensively. WCST consists of 13 test indicators and all indicators will be analyzed separately. The 13 indicators are as follows: number of trials administered; number of categories completed; response corrects; percent corrects; total number of errors; trials to complete first category; percent conceptual level responses; perseverative responses; perseverative errors; percent perseverative errors; nonperseverative errors; failure to maintain set; learning to learn. Percentage of the responses completed with 3-10 continuous correct during the entire measuring process was evaluated. Ranges from 0 to 100%, the more the better.
WCST: Perseverative Responses (Rp)Baseline and End of Week 12WCST is used to evaluate participants' abilities of abstract generalization, working memory, and distraction-cognitive clinically, which reflects participants' cognitive function objectively and comprehensively. WCST consists of 13 test indicators and all indicators will be analyzed separately. The 13 indicators are as follows: number of trials administered; number of categories completed; response corrects; percent corrects; total number of errors; trials to complete first category; percent conceptual level responses; perseverative responses; perseverative errors; percent perseverative errors; nonperseverative errors; failure to maintain set; learning to learn. Number of perseverative responses were the responses which applied continuity principle for matching answers was evaluated. Ranges from 0 to 100, the less the better.
WCST: Perseverative Error Responses (Rpe)Baseline and End of Week 12WCST is used to evaluate participants' abilities of abstract generalization, working memory, and distraction-cognitive clinically, which reflects participants' cognitive function objectively and comprehensively. WCST consists of 13 test indicators and all indicators will be analyzed separately. The 13 indicators are as follows: number of trials administered; number of categories completed; response corrects; percent corrects; total number of errors; trials to complete first category; percent conceptual level responses; perseverative responses; perseverative errors; percent perseverative errors; nonperseverative errors; failure to maintain set; learning to learn. Perseverative error responses are the number of responses which applied continuity principle for matching answers and also had the wrong answer was evaluated. Ranges from 0 to 128, the less the better.
WCST: Percentage of Perseverative Error Responses (Rpe%)Baseline and End of Week 12WCST is used to evaluate participants' abilities of abstract generalization, working memory, and distraction-cognitive clinically, which reflects participants' cognitive function objectively and comprehensively. WCST consists of 13 test indicators and all indicators will be analyzed separately. The 13 indicators are as follows: number of trials administered; number of categories completed; response corrects; percent corrects; total number of errors; trials to complete first category; percent conceptual level responses; perseverative responses; perseverative errors; percent perseverative (pvt) errors; nonperseverative errors; failure to maintain set; learning to learn. Percentage of persistent errors out of total number of responses was evaluated. Ranges from 0 to 100%, the less the better.
WCST: Non-Persistent Error Responses (nRpe)Baseline and End of Week 12WCST is used to evaluate participants' abilities of abstract generalization, working memory, and distraction-cognitive clinically, which reflects participants' cognitive function objectively and comprehensively. WCST consists of 13 test indicators and all indicators will be analyzed separately. The 13 indicators are as follows: number of trials administered; number of categories completed; response corrects; percent corrects; total number of errors; trials to complete first category; percent conceptual level responses; perseverative responses; perseverative errors; percent perseverative errors; nonperseverative errors; failure to maintain set; learning to learn. Non perseverative error responses are the errors remaining after subtracting persistent errors from total errors. Ranges from 0 to 128 and was not linear (cannot be considered to be good or bad just judged by the number, analyzed with other factors case by case).
WCST: Failure to Maintain Set (Fm)Baseline and End of Week 12WCST is used to evaluate participants' abilities of abstract generalization, working memory, and distraction-cognitive clinically, which reflects participants' cognitive function objectively and comprehensively. WCST consists of 13 test indicators and all indicators will be analyzed separately. The 13 indicators are as follows: number of trials administered; number of categories completed; response corrects; percent corrects; total number of errors; trials to complete first category; percent conceptual level responses; perseverative responses; perseverative errors; percent perseverative errors; nonperseverative errors; failure to maintain set; learning to learn. The frequency (number of times) of responses completed with 5 to 9 continuous correct was evaluated. Ranges from 0 to 26 and was not linear (cannot be considered to be good or bad just judged by the number, analyzed with other factors case by case).
Percentage of Participants With Total Score of IO Sub-scale Less Than or Equal to 5 in IOWA Conners Measurement Scale.End of Week 1, 2, 3, 7 and 12Remission rate is the percentage of participants with total score of IO sub-scale less than or equal to 5 in IOWA Conners measurement scale
Coding TestBaseline and End of Week 12The coding Test is a common test indicator for perceptual speed. The test presents a series of corresponding relationship between graphics and symbols to the participant, and then participants will be required to fill out the appropriate symbol following single symbol in the test part. The test is limited within 150 seconds and evaluated the number of symbols been replaced correctly by the participants.
Academic AchievementBaseline and End of Week 12Mathematics and language scores will be obtained from their corresponding examinations at school. Scores ranges from 0-100 respectively. Mathematics and language would be summarized separately.
Number of Participants With Clinical Global Impression - CGI Scale ScoreEnd of Week 1, 2, 3, 7 and 12CGI is an overall rating scale. Clinical Global Impression (Improvement of Diseases) is divided into seven grades: 1=very significant improvement, 24=significant improvement or advanced, 3=improvement or slightly advanced, 4=no change, 5=slight aggravation, 6=significant aggravation, and 7=very significant aggravation or seriously aggravated. Number of participants in each category of grade were assessed.
Change From Baseline in I/O Score of IOWA Conners Behavior Rating Scale at Week 12Baseline and End of Week 12IOWA conners behavior rating scale score in different dosage groups will be accessed to evaluate relationship between therapeutic effect and dosage. IOWA Conners Behavior Rating Scale evaluated by parents provides accurate measurement standards for behavioral change and therapeutic response. It includes 2 sub-scales: Inattention/Overactivity (I/O) subscale and Attacks (A), also known as Opposition/Defiant (O/D) sub-scale. IO (primary measurement ) will be assessed using 5-items and all Items will be scored on a 4-point scale (from 0=not at all to 3=very much). Total score range is from 0 to 15. Higher scores indicate worsening.
Number of Participants Compliant With TreatmentEnd of Week 12Number of Participants who are Compliant with Treatment will be accessed. Less than 80 percent and more than 120 percent compliance signifies bad compliance, 80 to 120 percent compliance signifies good compliance . The compliance was calculated by the percentage of dose (actual dose multiplied by 100/theoretical dose).The theoretical dose means the dose prescribed by the Investigator.
Change From Baseline in Total Scores of Digit Span Test at Week 12Baseline and End of Week 12The digit span test total score will be accessed in different dosage groups to evaluate the relationship between therapeutic effect and dosage. The digit span test is mainly used to measure the ability of short-term memory and attention. The participant will be given a string of digits and asked to repeat them forward, and then a second string of digits to repeat backward. The score is the number of correct responses, where the digits were repeated correctly. One point will be given for each correctly repeated string of digits. The maximum subscore in the Digits Forward is16, and the maximum subscore in the Digits Backward is 14, for a total score of 30. A higher score was indicative of better recall and attention.
Change From Baseline in Completion Time of Stroop Color-word Test at Week 12Baseline and End of Week 12Completion time of stroop color-word test in different dosage groups will be accessed to evaluate the relationship between therapeutic effect and dosage. This is a psychological test to observe the interference in which disparity between the meaning and color affects reading speed. A participant will be given 3 tasks of recognition: reading the printed colored ink (Color Test), reading color words in black ink (Word Test), and interference, reading color words printed in different colored ink (Word-Color Test). The test will be scored on the number of correct answers. There are 100 items for each of the three categories and if they made it through the 100 words with time remaining, they would repeat the list. Median time of the naming time in the Stroop color word naming test will be accessed. Stroop color word naming test 1 ,2 ,3 and 4 stand for gradually increased difficulty and each test has a corresponding baseline and endpoint.
Percentage of Participants With Total Score of IO Sub-scale Less Than or Equal to 5 in IOWA Conners Measurement Scale at Week 12Week 12Remission rate in different dosage groups will be accessed to evaluate the relationship between therapeutic effect and dosage. Remission rate is the percentage of participants with total score of IO sub-scale less than or equal to 5 in IOWA Conners measurement scale.
WCST: Learning to Learn (L-C)Baseline and End of Week 12WCST is used to evaluate participants' abilities of abstract generalization, working memory, and distraction-cognitive clinically, which reflects participants' cognitive function objectively and comprehensively. WCST consists of 13 test indicators and all indicators will be analyzed separately. Learning to learn indicator was a measure of decrement in the number of responses needed to achieve each successive category. The raw score ranged from 0 to 100. The high, negative value suggests the participants could not effectively learn the task presented by the WCST. Only calculated in those completed 3 or more categories and not linear (cannot be considered to be good or bad just judged by the number, analyzed with other factors case by case).
Stroop Color Word Naming TestBaseline and End of Week 12This is a psychological test to observe the interference in which disparity between the meaning and color affects reading speed. A participant will be given 3 tasks of recognition: reading the printed colored ink (Color Test), reading color words in black ink (Word Test), and interference, reading color words printed in different colored ink (Word-Color Test). The test is scored on the number of correct answers. There are 100 items for each of the three categories and if they made it through the 100 words with time remaining, they would repeat the list. Median naming time in the Stroop color word naming test will be assessed. Stroop color word naming test 1 ,2 ,3 and 4 stand for gradually increased difficulty and each test has a corresponding baseline and endpoint.
Wisconsin Card Sorting Test (WCST): Administered Responses (Ra) of Completed ExaminationBaseline and End of Week 12WCST is used to evaluate participants' abilities of abstract generalization, working memory, and distraction-cognitive clinically, which reflects participants' cognitive function objectively and comprehensively. WCST consists of 13 test indicators and all indicators will be analyzed separately. The 13 indicators are as follows: number of trials administered; number of categories completed; response corrects; percent corrects; total number of errors; trials to complete first category; percent conceptual level responses; perseverative responses; perseverative errors; percent perseverative errors; nonperseverative errors; failure to maintain set; learning to learn. During number of trials administered or administered responses, participants were administered 128 cards and asked to sort the cards until all the 6 sorting categories was completed. Response number used to complete all 6 categories ranges from 50 to 128, lesser the better.
WCST: Completed Categories (Cc)Baseline and End of Week 12WCST is used to evaluate participants' abilities of abstract generalization, working memory, and distraction-cognitive clinically, which reflects participants' cognitive function objectively and comprehensively. WCST consists of 13 test indicators and all indicators will be analyzed separately. The 13 indicators are as follows: number of trials administered; number of categories completed; response corrects; percent corrects; total number of errors; trials to complete first category; percent conceptual level responses; perseverative responses; perseverative errors; percent perseverative errors; nonperseverative errors; failure to maintain set; learning to learn. In completed categoriies, number of categories completed out of 6 sorting categories after the test was evaluated. Ranges from 0 to 6. The more the number of categories completed the better is the response.
WCST: Correct Responses (Rc)Baseline and End of Week 12WCST is used to evaluate participants' abilities of abstract generalization, working memory, and distraction-cognitive clinically, which reflects participants' cognitive function objectively and comprehensively. WCST consists of 13 test indicators and all indicators will be analyzed separately. The 13 indicators are as follows: number of trials administered; number of categories completed; response corrects; percent corrects; total number of errors; trials to complete first category; percent conceptual level responses; perseverative responses; perseverative errors; percent perseverative errors; nonperseverative errors; failure to maintain set; learning to learn. The number of correct responses which meets all the requirements according to the response principles was evaluated. Ranges from 0-116, the more the better.
WCST: Error Responses (Re)Baseline and End of Week 12WCST is used to evaluate participants' abilities of abstract generalization, working memory, and distraction-cognitive clinically, which reflects participants' cognitive function objectively and comprehensively. WCST consists of 13 test indicators and all indicators will be analyzed separately. The 13 indicators are as follows: number of trials administered; number of categories completed; response corrects; percent corrects; total number of errors; trials to complete first category; percent conceptual level responses; perseverative responses; perseverative errors; percent perseverative errors; nonperseverative errors; failure to maintain set; learning to learn. Number of error responses which did not comply with the response principles was evaluated. Ranges from 0 to 128, the less the better.

Countries

China

Participant flow

Participants by arm

ArmCount
OROS-MPH Group
Participants with attention deficit hyperactivity disorder (ADHD) received osmotic release oral system-methylphenidate (OROS-MPH) tablets orally daily, starting at initial dosage of 18 milligram per day (mg/d) which could be increased to 36 mg/d up to a maximum dosage of 54 mg/d according to the therapeutic effect and tolerance or maintained at 36 mg or re-adjusted to 18 mg due to intolerance.
128
Normal Group
Participants did not receive any study drug in this group. Participants were assessed for changes in the cognitive functions and the efficacy was compared with ADHD children.
40
Total168

Withdrawals & dropouts

PeriodReasonFG000FG001
Overall StudyConcomitant medication Interference01
Overall StudyFollowup exceeded 4 days to visit window190
Overall StudyLack of Efficacy10
Overall StudyOther40
Overall StudyProtocol Violation10
Overall StudyWithdrawal by Subject50

Baseline characteristics

CharacteristicOROS-MPH GroupNormal GroupTotal
Age, Customized
11 to 12 Years
25 participants14 participants39 participants
Age, Customized
9 to 10 Years
55 participants16 participants71 participants
Age, Customized
Less than 7 to 8 Years
48 participants
1.47
10 participants
1.72
58 participants
Sex: Female, Male
Female
20 Participants17 Participants37 Participants
Sex: Female, Male
Male
108 Participants23 Participants131 Participants

Adverse events

Event typeEG000
affected / at risk
deaths
Total, all-cause mortality
— / —
other
Total, other adverse events
27 / 149
serious
Total, serious adverse events
0 / 149

Outcome results

Primary

Change From Baseline in Digit Span Test Total Score at Week 12

The digit span test is mainly used to measure the ability of short-term memory and attention. The participant will be given a string of digits and asked to repeat them forward, and then a second string of digits to repeat backward. The score is the number of correct responses, where the digits were repeated correctly. One point will be given for each correctly repeated string of digits. The maximum subscore in the Digits Forward is 16, and the maximum subscore in the Digits Backward is 14, summed for a total score of 30. A higher score is indicative of better recall and attention.

Time frame: Baseline and Week 12

Population: Full Analysis Set (FAS) population for OROS-MPH Group included all participants who received at least one study drug therapy and had at least one efficacy evaluation. FAS for normal group included all participants who received baseline assessment scale evaluation and had at least one endpoint assessment scale evaluation.

ArmMeasureGroupValue (MEAN)Dispersion
OROS-MPH GroupChange From Baseline in Digit Span Test Total Score at Week 12Baseline11.7 Scores on a scaleStandard Deviation 2.25
OROS-MPH GroupChange From Baseline in Digit Span Test Total Score at Week 12Change at Week 121 Scores on a scaleStandard Deviation 1.5
Normal GroupChange From Baseline in Digit Span Test Total Score at Week 12Baseline13.7 Scores on a scaleStandard Deviation 2.43
Normal GroupChange From Baseline in Digit Span Test Total Score at Week 12Change at Week 120.5 Scores on a scaleStandard Deviation 1.48
Comparison: P-value was calculated to compare the data at Baseline and change at Week 12 for the OROS-MPH groupp-value: 0.0387Signed Rank Sum Test
Primary

Change From Baseline in Inattention/Overactivity With Aggression (IOWA) Conners Behavior Rating Scale - I/O Score at Week 1

IOWA Conners Behavior Rating Scale evaluated by parents provides accurate measurement standards for behavioral change and therapeutic response. It includes 2 sub-scales: Inattention/Overactivity (I/O) subscale and Attacks (A), also known as Opposition/Defiant (O/D) sub-scale. IO (primary measurement ) will be assessed using 5-items and all Items will be scored on a 4-point scale (from 0=not at all to 3=very much). Total score range is from 0 to 15. Higher scores indicate worsening.

Time frame: Baseline and Week 1

Population: FAS population for OROS-MPH Group. Here N signifies number of participants who were evaluable for this outcome measure. Data for Normal group was not analyzed for IOWA Conners scale since as per the planned analysis normal participants were only analyzed for the memory effect in cognitive function test.

ArmMeasureGroupValue (MEAN)Dispersion
OROS-MPH GroupChange From Baseline in Inattention/Overactivity With Aggression (IOWA) Conners Behavior Rating Scale - I/O Score at Week 1Baseline10 Scores on a scaleStandard Deviation 2.4
OROS-MPH GroupChange From Baseline in Inattention/Overactivity With Aggression (IOWA) Conners Behavior Rating Scale - I/O Score at Week 1Change at Week 1-2.7 Scores on a scaleStandard Deviation 2.18
Comparison: P-value was calculated to compare the data at Baseline and change at Week 1 for the OROS-MPH groupp-value: <0.0001t-test, 2 sided
Primary

Change From Baseline in IOWA Conners Behavior Rating Scale - I/O Score at Week 12

IOWA Conners Behavior Rating Scale evaluated by parents provides accurate measurement standards for behavioral change and therapeutic response. It includes 2 sub-scales: Inattention/Overactivity (I/O) subscale and Attacks (A), also known as Opposition/Defiant (O/D) sub-scale. IO (primary measurement ) will be assessed using 5-items and all Items will be scored on a 4-point scale (from 0=not at all to 3=very much). Total score range is from 0 to 15. Higher scores indicate worsening.

Time frame: Baseline and Week 12

Population: FAS population for OROS-MPH Group. Here N signifies number of participants who were evaluable for this outcome measure. Data for Normal group was not analyzed for IOWA Conners scale since as per the planned analysis normal participants were only analyzed for the memory effect in cognitive function test.

ArmMeasureGroupValue (MEAN)Dispersion
OROS-MPH GroupChange From Baseline in IOWA Conners Behavior Rating Scale - I/O Score at Week 12Baseline10 Scores on a scaleStandard Deviation 2.4
OROS-MPH GroupChange From Baseline in IOWA Conners Behavior Rating Scale - I/O Score at Week 12Change at Week 12-6.2 Scores on a scaleStandard Deviation 3.08
Comparison: P-value was calculated to compare the data at Baseline and change at Week 12 for the OROS-MPH groupp-value: <0.0001t-test, 2 sided
Primary

Change From Baseline in IOWA Conners Behavior Rating Scale - I/O Score at Week 2

IOWA Conners Behavior Rating Scale evaluated by parents provides accurate measurement standards for behavioral change and therapeutic response. It includes 2 sub-scales: Inattention/Overactivity (I/O) subscale and Attacks (A), also known as Opposition/Defiant (O/D) sub-scale. IO (primary measurement ) will be assessed using 5-items and all Items will be scored on a 4-point scale (from 0=not at all to 3=very much). Total score range is from 0 to 15. Higher scores indicate worsening.

Time frame: Baseline and Week 2

Population: FAS population for OROS-MPH Group. Here N signifies number of participants who were evaluable for this outcome measure. Data for Normal group was not analyzed for IOWA Conners scale since as per the planned analysis normal participants were only analyzed for the memory effect in cognitive function test.

ArmMeasureGroupValue (MEAN)Dispersion
OROS-MPH GroupChange From Baseline in IOWA Conners Behavior Rating Scale - I/O Score at Week 2Baseline10 Scores on a scaleStandard Deviation 2.4
OROS-MPH GroupChange From Baseline in IOWA Conners Behavior Rating Scale - I/O Score at Week 2Change at Week 2-4.1 Scores on a scaleStandard Deviation 2.73
Comparison: P-value was calculated to compare the data at Baseline and change at Week 2 for the OROS-MPH groupp-value: 0.0001t-test, 2 sided
Primary

Change From Baseline in IOWA Conners Behavior Rating Scale - I/O Score at Week 3

IOWA Conners Behavior Rating Scale evaluated by parents provides accurate measurement standards for behavioral change and therapeutic response. It includes 2 sub-scales: Inattention/Overactivity (I/O) subscale and Attacks (A), also known as Opposition/Defiant (O/D) sub-scale. IO (primary measurement ) will be assessed using 5-items and all Items will be scored on a 4-point scale (from 0=not at all to 3=very much). Total score range is from 0 to 15. Higher scores indicate worsening.

Time frame: Baseline and Week 3

Population: FAS population for OROS-MPH Group. Here N signifies number of participants who were evaluable for this outcome measure. Data for Normal group was not analyzed for IOWA Conners scale since as per the planned analysis normal participants were only analyzed for the memory effect in cognitive function test.

ArmMeasureGroupValue (MEAN)Dispersion
OROS-MPH GroupChange From Baseline in IOWA Conners Behavior Rating Scale - I/O Score at Week 3Baseline10 Scores on a scaleStandard Deviation 2.4
OROS-MPH GroupChange From Baseline in IOWA Conners Behavior Rating Scale - I/O Score at Week 3Change at Week 3-5 Scores on a scaleStandard Deviation 2.81
Comparison: P-value was calculated to compare the data at Baseline and change at Week 3 for the OROS-MPH groupp-value: <0.0001t-test, 2 sided
Primary

Change From Baseline in IOWA Conners Behavior Rating Scale - I/O Score at Week 7

IOWA Conners Behavior Rating Scale evaluated by parents provides accurate measurement standards for behavioral change and therapeutic response. It includes 2 sub-scales: Inattention/Overactivity (I/O) subscale and Attacks (A), also known as Opposition/Defiant (O/D) sub-scale. IO (primary measurement ) will be assessed using 5-items and all Items will be scored on a 4-point scale (from 0=not at all to 3=very much). Total score range is from 0 to 15. Higher scores indicate worsening.

Time frame: Baseline and Week 7

Population: FAS population for OROS-MPH Group. Here N signifies number of participants who were evaluable for this outcome measure. Data for Normal group was not analyzed for IOWA Conners scale since as per the planned analysis normal participants were only analyzed for the memory effect in cognitive function test.

ArmMeasureGroupValue (MEAN)Dispersion
OROS-MPH GroupChange From Baseline in IOWA Conners Behavior Rating Scale - I/O Score at Week 7Baseline10 Scores on a scaleStandard Deviation 2.4
OROS-MPH GroupChange From Baseline in IOWA Conners Behavior Rating Scale - I/O Score at Week 7Change at Week 7-5.8 Scores on a scaleStandard Deviation 2.91
Comparison: P-value was calculated to compare the data at Baseline and change at Week 7 for the OROS-MPH groupp-value: <0.0001t-test, 2 sided
Secondary

Academic Achievement

Mathematics and language scores will be obtained from their corresponding examinations at school. Scores ranges from 0-100 respectively. Mathematics and language would be summarized separately.

Time frame: Baseline and End of Week 12

Population: FAS population for OROS-MPH Group included participants who received at least 1 study drug and had at least one efficacy evaluation. FAS for normal group included all participants who had baseline scale evaluation and had at least one endpoint scale evaluation. n signifies participants who were evaluable at each time point for each specific arm.

ArmMeasureGroupValue (MEAN)Dispersion
OROS-MPH GroupAcademic AchievementChinese Achievement: Basline (n=128, 40)77.35 scores on a scaleStandard Deviation 13.791
OROS-MPH GroupAcademic AchievementChinese Achievement: End of Week 12(n=111, 40)83.94 scores on a scaleStandard Deviation 10.737
OROS-MPH GroupAcademic AchievementMathematical Achievement (MA):Baseline (n=128, 40)78.86 scores on a scaleStandard Deviation 15.407
OROS-MPH GroupAcademic AchievementMA: End of Week 12 (n=111, 40)86.05 scores on a scaleStandard Deviation 11.579
Normal GroupAcademic AchievementMA: End of Week 12 (n=111, 40)96.13 scores on a scaleStandard Deviation 3.625
Normal GroupAcademic AchievementChinese Achievement: Basline (n=128, 40)94.21 scores on a scaleStandard Deviation 4.301
Normal GroupAcademic AchievementMathematical Achievement (MA):Baseline (n=128, 40)96.23 scores on a scaleStandard Deviation 3.641
Normal GroupAcademic AchievementChinese Achievement: End of Week 12(n=111, 40)94.56 scores on a scaleStandard Deviation 4.396
Secondary

Change From Baseline in Completion Time of Stroop Color-word Test at Week 12

Completion time of stroop color-word test in different dosage groups will be accessed to evaluate the relationship between therapeutic effect and dosage. This is a psychological test to observe the interference in which disparity between the meaning and color affects reading speed. A participant will be given 3 tasks of recognition: reading the printed colored ink (Color Test), reading color words in black ink (Word Test), and interference, reading color words printed in different colored ink (Word-Color Test). The test will be scored on the number of correct answers. There are 100 items for each of the three categories and if they made it through the 100 words with time remaining, they would repeat the list. Median time of the naming time in the Stroop color word naming test will be accessed. Stroop color word naming test 1 ,2 ,3 and 4 stand for gradually increased difficulty and each test has a corresponding baseline and endpoint.

Time frame: Baseline and End of Week 12

Population: FAS population for OROS-MPH Group included all participants who received at least one study drug therapy and had at least one efficacy evaluation. Here N signifies participants who were evaluable for this outcome measure and n signifies participants who were evaluable at each time point for each specific arm.

ArmMeasureGroupValue (MEAN)Dispersion
OROS-MPH GroupChange From Baseline in Completion Time of Stroop Color-word Test at Week 12Test 4: Baseline (n=86, 30, 1)23.61 SecondsStandard Deviation 12.135
OROS-MPH GroupChange From Baseline in Completion Time of Stroop Color-word Test at Week 12Test 2: Baseline (n=86, 30, 1)20.538 SecondsStandard Deviation 15.3567
OROS-MPH GroupChange From Baseline in Completion Time of Stroop Color-word Test at Week 12Test 2: Change at End of Week 12 (n=82, 27, 1)-2.164 SecondsStandard Deviation 5.2669
OROS-MPH GroupChange From Baseline in Completion Time of Stroop Color-word Test at Week 12Test 4: Change at End of Week 12 (n=82, 27, 1)-4.374 SecondsStandard Deviation 7.5921
OROS-MPH GroupChange From Baseline in Completion Time of Stroop Color-word Test at Week 12Test 1: Baseline (n=86, 30, 1)22.229 SecondsStandard Deviation 18.7304
OROS-MPH GroupChange From Baseline in Completion Time of Stroop Color-word Test at Week 12Test 3: Baseline (n=86, 30, 1)19.515 SecondsStandard Deviation 14.6203
OROS-MPH GroupChange From Baseline in Completion Time of Stroop Color-word Test at Week 12Test 1: Change at End of Week 12 (n=82, 27, 1)-3.318 SecondsStandard Deviation 5.6413
OROS-MPH GroupChange From Baseline in Completion Time of Stroop Color-word Test at Week 12Test 3: Change at End of Week 12 (n=82, 27, 1)-2.336 SecondsStandard Deviation 5.3987
Normal GroupChange From Baseline in Completion Time of Stroop Color-word Test at Week 12Test 1: Change at End of Week 12 (n=82, 27, 1)-1 SecondsStandard Deviation 4.308
Normal GroupChange From Baseline in Completion Time of Stroop Color-word Test at Week 12Test 3: Change at End of Week 12 (n=82, 27, 1)-2.996 SecondsStandard Deviation 6.6313
Normal GroupChange From Baseline in Completion Time of Stroop Color-word Test at Week 12Test 4: Change at End of Week 12 (n=82, 27, 1)-3.974 SecondsStandard Deviation 6.0143
Normal GroupChange From Baseline in Completion Time of Stroop Color-word Test at Week 12Test 2: Baseline (n=86, 30, 1)17.29 SecondsStandard Deviation 11.7025
Normal GroupChange From Baseline in Completion Time of Stroop Color-word Test at Week 12Test 1: Baseline (n=86, 30, 1)17.7 SecondsStandard Deviation 13.654
Normal GroupChange From Baseline in Completion Time of Stroop Color-word Test at Week 12Test 2: Change at End of Week 12 (n=82, 27, 1)-1.233 SecondsStandard Deviation 3.9809
Normal GroupChange From Baseline in Completion Time of Stroop Color-word Test at Week 12Test 4: Baseline (n=86, 30, 1)22.154 SecondsStandard Deviation 9.2451
Normal GroupChange From Baseline in Completion Time of Stroop Color-word Test at Week 12Test 3: Baseline (n=86, 30, 1)17.473 SecondsStandard Deviation 14.2673
OROS-MPH Group 54 mgChange From Baseline in Completion Time of Stroop Color-word Test at Week 12Test 4: Change at End of Week 12 (n=82, 27, 1)1 SecondsStandard Deviation 0
OROS-MPH Group 54 mgChange From Baseline in Completion Time of Stroop Color-word Test at Week 12Test 1: Baseline (n=86, 30, 1)5 SecondsStandard Deviation 0
OROS-MPH Group 54 mgChange From Baseline in Completion Time of Stroop Color-word Test at Week 12Test 1: Change at End of Week 12 (n=82, 27, 1)0 SecondsStandard Deviation 0
OROS-MPH Group 54 mgChange From Baseline in Completion Time of Stroop Color-word Test at Week 12Test 2: Baseline (n=86, 30, 1)9 SecondsStandard Deviation 0
OROS-MPH Group 54 mgChange From Baseline in Completion Time of Stroop Color-word Test at Week 12Test 2: Change at End of Week 12 (n=82, 27, 1)0 SecondsStandard Deviation 0
OROS-MPH Group 54 mgChange From Baseline in Completion Time of Stroop Color-word Test at Week 12Test 3: Baseline (n=86, 30, 1)7 SecondsStandard Deviation 0
OROS-MPH Group 54 mgChange From Baseline in Completion Time of Stroop Color-word Test at Week 12Test 3: Change at End of Week 12 (n=82, 27, 1)3 SecondsStandard Deviation 0
OROS-MPH Group 54 mgChange From Baseline in Completion Time of Stroop Color-word Test at Week 12Test 4: Baseline (n=86, 30, 1)15 SecondsStandard Deviation 0
Secondary

Change From Baseline in I/O Score of IOWA Conners Behavior Rating Scale at Week 12

IOWA conners behavior rating scale score in different dosage groups will be accessed to evaluate relationship between therapeutic effect and dosage. IOWA Conners Behavior Rating Scale evaluated by parents provides accurate measurement standards for behavioral change and therapeutic response. It includes 2 sub-scales: Inattention/Overactivity (I/O) subscale and Attacks (A), also known as Opposition/Defiant (O/D) sub-scale. IO (primary measurement ) will be assessed using 5-items and all Items will be scored on a 4-point scale (from 0=not at all to 3=very much). Total score range is from 0 to 15. Higher scores indicate worsening.

Time frame: Baseline and End of Week 12

Population: FAS population for OROS-MPH Group included all participants who received at least one study drug therapy and had at least one efficacy evaluation. Here N signifies participants who were evaluable for this outcome measure.

ArmMeasureGroupValue (MEAN)Dispersion
OROS-MPH GroupChange From Baseline in I/O Score of IOWA Conners Behavior Rating Scale at Week 12Baseline10 Scores on a scaleStandard Deviation 2.42
OROS-MPH GroupChange From Baseline in I/O Score of IOWA Conners Behavior Rating Scale at Week 12Change at End of Week 12-6.8 Scores on a scaleStandard Deviation 2.82
Normal GroupChange From Baseline in I/O Score of IOWA Conners Behavior Rating Scale at Week 12Baseline10.3 Scores on a scaleStandard Deviation 2.39
Normal GroupChange From Baseline in I/O Score of IOWA Conners Behavior Rating Scale at Week 12Change at End of Week 12-5.8 Scores on a scaleStandard Deviation 3.32
OROS-MPH Group 54 mgChange From Baseline in I/O Score of IOWA Conners Behavior Rating Scale at Week 12Baseline7 Scores on a scaleStandard Deviation 0
OROS-MPH Group 54 mgChange From Baseline in I/O Score of IOWA Conners Behavior Rating Scale at Week 12Change at End of Week 12-4 Scores on a scaleStandard Deviation 0
Secondary

Change From Baseline in Total Scores of Digit Span Test at Week 12

The digit span test total score will be accessed in different dosage groups to evaluate the relationship between therapeutic effect and dosage. The digit span test is mainly used to measure the ability of short-term memory and attention. The participant will be given a string of digits and asked to repeat them forward, and then a second string of digits to repeat backward. The score is the number of correct responses, where the digits were repeated correctly. One point will be given for each correctly repeated string of digits. The maximum subscore in the Digits Forward is16, and the maximum subscore in the Digits Backward is 14, for a total score of 30. A higher score was indicative of better recall and attention.

Time frame: Baseline and End of Week 12

Population: FAS population for OROS-MPH Group included all participants who received at least one study drug therapy and had at least one efficacy evaluation. Here N signifies participants who were evaluable for this outcome measure.

ArmMeasureGroupValue (MEAN)Dispersion
OROS-MPH GroupChange From Baseline in Total Scores of Digit Span Test at Week 12Baseline11.7 Scores on a scaleStandard Deviation 2.4
OROS-MPH GroupChange From Baseline in Total Scores of Digit Span Test at Week 12Change at End of Week 121.2 Scores on a scaleStandard Deviation 1.54
Normal GroupChange From Baseline in Total Scores of Digit Span Test at Week 12Baseline11.3 Scores on a scaleStandard Deviation 1.95
Normal GroupChange From Baseline in Total Scores of Digit Span Test at Week 12Change at End of Week 120.8 Scores on a scaleStandard Deviation 1.56
OROS-MPH Group 54 mgChange From Baseline in Total Scores of Digit Span Test at Week 12Change at End of Week 120 Scores on a scaleStandard Deviation 0
OROS-MPH Group 54 mgChange From Baseline in Total Scores of Digit Span Test at Week 12Baseline15 Scores on a scaleStandard Deviation 0
Secondary

Coding Test

The coding Test is a common test indicator for perceptual speed. The test presents a series of corresponding relationship between graphics and symbols to the participant, and then participants will be required to fill out the appropriate symbol following single symbol in the test part. The test is limited within 150 seconds and evaluated the number of symbols been replaced correctly by the participants.

Time frame: Baseline and End of Week 12

Population: FAS population for OROS-MPH Group included participants who received at least 1 study drug and had at least one efficacy evaluation. FAS for normal group included all participants who had baseline scale evaluation and had at least one endpoint scale evaluation. n signifies participants who were evaluable at each time point for each specific arm.

ArmMeasureGroupValue (MEAN)Dispersion
OROS-MPH GroupCoding TestBaseline (n=128, 40)63.4 Number of symbols correctly replacedStandard Deviation 40.14
OROS-MPH GroupCoding TestEnd of Week 12 (n=111, 40)73.2 Number of symbols correctly replacedStandard Deviation 41.41
Normal GroupCoding TestBaseline (n=128, 40)77.4 Number of symbols correctly replacedStandard Deviation 44.83
Normal GroupCoding TestEnd of Week 12 (n=111, 40)83.1 Number of symbols correctly replacedStandard Deviation 44.19
Secondary

Number of Participants Compliant With Treatment

Number of Participants who are Compliant with Treatment will be accessed. Less than 80 percent and more than 120 percent compliance signifies bad compliance, 80 to 120 percent compliance signifies good compliance . The compliance was calculated by the percentage of dose (actual dose multiplied by 100/theoretical dose).The theoretical dose means the dose prescribed by the Investigator.

Time frame: End of Week 12

Population: FAS population for OROS-MPH Group. Here N signifies participants who were evaluable for this outcome measure. Data for Normal group was not analyzed for IOWA Conners scale since as per the planned analysis normal participants were only analyzed for the memory effect in cognitive function test.

ArmMeasureGroupValue (NUMBER)
OROS-MPH GroupNumber of Participants Compliant With TreatmentLess than 80 percent17 participants
OROS-MPH GroupNumber of Participants Compliant With TreatmentBetween 80 to 120 percent110 participants
OROS-MPH GroupNumber of Participants Compliant With TreatmentMore than 120 percent0 participants
Secondary

Number of Participants With Clinical Global Impression - CGI Scale Score

CGI is an overall rating scale. Clinical Global Impression (Improvement of Diseases) is divided into seven grades: 1=very significant improvement, 24=significant improvement or advanced, 3=improvement or slightly advanced, 4=no change, 5=slight aggravation, 6=significant aggravation, and 7=very significant aggravation or seriously aggravated. Number of participants in each category of grade were assessed.

Time frame: End of Week 1, 2, 3, 7 and 12

Population: FAS population for OROS-MPH Group included all participants who received at least one study drug therapy and had at least one efficacy evaluation. Data for Normal group was not analyzed for IOWA Conners scale since as per the planned analysis normal participants were only analyzed for the memory effect in cognitive function test

ArmMeasureGroupValue (NUMBER)
OROS-MPH GroupNumber of Participants With Clinical Global Impression - CGI Scale ScoreSlightly Aggravated: End of Week 121 Participants
OROS-MPH GroupNumber of Participants With Clinical Global Impression - CGI Scale ScoreAggravated: End of Week 10 Participants
OROS-MPH GroupNumber of Participants With Clinical Global Impression - CGI Scale ScoreAggravated: End of Week 30 Participants
OROS-MPH GroupNumber of Participants With Clinical Global Impression - CGI Scale ScoreAggravated: End of Week 70 Participants
OROS-MPH GroupNumber of Participants With Clinical Global Impression - CGI Scale ScoreSeriously Aggravated: End of Week 70 Participants
OROS-MPH GroupNumber of Participants With Clinical Global Impression - CGI Scale ScoreAdvanced: End of Week 741 Participants
OROS-MPH GroupNumber of Participants With Clinical Global Impression - CGI Scale ScoreAdvanced: End of Week 1246 Participants
OROS-MPH GroupNumber of Participants With Clinical Global Impression - CGI Scale ScoreSlightly Advanced: End of Week 133 Participants
OROS-MPH GroupNumber of Participants With Clinical Global Impression - CGI Scale ScoreSlightly Advanced: End of Week 228 Participants
OROS-MPH GroupNumber of Participants With Clinical Global Impression - CGI Scale ScoreSlightly Advanced: End of Week 333 Participants
OROS-MPH GroupNumber of Participants With Clinical Global Impression - CGI Scale ScoreSlightly Advanced: End of Week 728 Participants
OROS-MPH GroupNumber of Participants With Clinical Global Impression - CGI Scale ScoreSlightly Advanced: End of Week 1225 Participants
OROS-MPH GroupNumber of Participants With Clinical Global Impression - CGI Scale ScoreNo Change: End of Week 115 Participants
OROS-MPH GroupNumber of Participants With Clinical Global Impression - CGI Scale ScoreNo Change: End of Week 210 Participants
OROS-MPH GroupNumber of Participants With Clinical Global Impression - CGI Scale ScoreNo Change: End of Week 311 Participants
OROS-MPH GroupNumber of Participants With Clinical Global Impression - CGI Scale ScoreNo Change: End of Week 77 Participants
OROS-MPH GroupNumber of Participants With Clinical Global Impression - CGI Scale ScoreNo Change: End of Week 123 Participants
OROS-MPH GroupNumber of Participants With Clinical Global Impression - CGI Scale ScoreSlightly Aggravated: End of Week 10 Participants
OROS-MPH GroupNumber of Participants With Clinical Global Impression - CGI Scale ScoreSlightly Aggravated: End of Week 22 Participants
OROS-MPH GroupNumber of Participants With Clinical Global Impression - CGI Scale ScoreSlightly Aggravated: End of Week 30 Participants
OROS-MPH GroupNumber of Participants With Clinical Global Impression - CGI Scale ScoreSlightly Aggravated: End of Week 73 Participants
OROS-MPH GroupNumber of Participants With Clinical Global Impression - CGI Scale ScoreAggravated: End of Week 20 Participants
OROS-MPH GroupNumber of Participants With Clinical Global Impression - CGI Scale ScoreAggravated: End of Week 120 Participants
OROS-MPH GroupNumber of Participants With Clinical Global Impression - CGI Scale ScoreSeriously Aggravated: End of Week 10 Participants
OROS-MPH GroupNumber of Participants With Clinical Global Impression - CGI Scale ScoreSeriously Aggravated: End of Week 20 Participants
OROS-MPH GroupNumber of Participants With Clinical Global Impression - CGI Scale ScoreSeriously Aggravated: End of Week 30 Participants
OROS-MPH GroupNumber of Participants With Clinical Global Impression - CGI Scale ScoreSeriously Aggravated: End of Week 120 Participants
OROS-MPH GroupNumber of Participants With Clinical Global Impression - CGI Scale ScoreSignificantly Advanced: End of Week 120 Participants
OROS-MPH GroupNumber of Participants With Clinical Global Impression - CGI Scale ScoreSignificantly Advanced: End of Week 228 Participants
OROS-MPH GroupNumber of Participants With Clinical Global Impression - CGI Scale ScoreSignificantly Advanced: End of Week 329 Participants
OROS-MPH GroupNumber of Participants With Clinical Global Impression - CGI Scale ScoreSignificantly Advanced: End of Week 735 Participants
OROS-MPH GroupNumber of Participants With Clinical Global Impression - CGI Scale ScoreSignificantly Advanced: End of Week 1236 Participants
OROS-MPH GroupNumber of Participants With Clinical Global Impression - CGI Scale ScoreAdvanced: End of Week 159 Participants
OROS-MPH GroupNumber of Participants With Clinical Global Impression - CGI Scale ScoreAdvanced: End of Week 253 Participants
OROS-MPH GroupNumber of Participants With Clinical Global Impression - CGI Scale ScoreAdvanced: End of Week 344 Participants
Secondary

Percentage of Participants With Total Score of IO Sub-scale Less Than or Equal to 5 in IOWA Conners Measurement Scale.

Remission rate is the percentage of participants with total score of IO sub-scale less than or equal to 5 in IOWA Conners measurement scale

Time frame: End of Week 1, 2, 3, 7 and 12

Population: FAS population for OROS-MPH Group included all participants who received at least one study drug therapy and had at least one efficacy evaluation. Data for Normal group was not analyzed for IOWA Conners scale since as per the planned analysis normal participants were only analyzed for the memory effect in cognitive function test.

ArmMeasureGroupValue (NUMBER)
OROS-MPH GroupPercentage of Participants With Total Score of IO Sub-scale Less Than or Equal to 5 in IOWA Conners Measurement Scale.End of Week 125.98 Percentage of Participants
OROS-MPH GroupPercentage of Participants With Total Score of IO Sub-scale Less Than or Equal to 5 in IOWA Conners Measurement Scale.End of Week 251.97 Percentage of Participants
OROS-MPH GroupPercentage of Participants With Total Score of IO Sub-scale Less Than or Equal to 5 in IOWA Conners Measurement Scale.End of Week 366.93 Percentage of Participants
OROS-MPH GroupPercentage of Participants With Total Score of IO Sub-scale Less Than or Equal to 5 in IOWA Conners Measurement Scale.End of Week 778.74 Percentage of Participants
OROS-MPH GroupPercentage of Participants With Total Score of IO Sub-scale Less Than or Equal to 5 in IOWA Conners Measurement Scale.End of Week 1281.10 Percentage of Participants
Secondary

Percentage of Participants With Total Score of IO Sub-scale Less Than or Equal to 5 in IOWA Conners Measurement Scale at Week 12

Remission rate in different dosage groups will be accessed to evaluate the relationship between therapeutic effect and dosage. Remission rate is the percentage of participants with total score of IO sub-scale less than or equal to 5 in IOWA Conners measurement scale.

Time frame: Week 12

Population: FAS population for OROS-MPH Group included all participants who received at least one study drug therapy and had at least one efficacy evaluation. Here N signifies participants who were evaluable for this outcome measure.

ArmMeasureValue (NUMBER)
OROS-MPH GroupPercentage of Participants With Total Score of IO Sub-scale Less Than or Equal to 5 in IOWA Conners Measurement Scale at Week 1285.37 Percentage of participants
Normal GroupPercentage of Participants With Total Score of IO Sub-scale Less Than or Equal to 5 in IOWA Conners Measurement Scale at Week 1274.07 Percentage of participants
OROS-MPH Group 54 mgPercentage of Participants With Total Score of IO Sub-scale Less Than or Equal to 5 in IOWA Conners Measurement Scale at Week 12100.00 Percentage of participants
Secondary

Stroop Color Word Naming Test

This is a psychological test to observe the interference in which disparity between the meaning and color affects reading speed. A participant will be given 3 tasks of recognition: reading the printed colored ink (Color Test), reading color words in black ink (Word Test), and interference, reading color words printed in different colored ink (Word-Color Test). The test is scored on the number of correct answers. There are 100 items for each of the three categories and if they made it through the 100 words with time remaining, they would repeat the list. Median naming time in the Stroop color word naming test will be assessed. Stroop color word naming test 1 ,2 ,3 and 4 stand for gradually increased difficulty and each test has a corresponding baseline and endpoint.

Time frame: Baseline and End of Week 12

Population: FAS for OROS-MPH Group included participants who took at least 1 study drug therapy and had at least 1 efficacy evaluation. FAS for normal group included participants who had baseline assessment scale evaluation and had at least 1 endpoint assessment scale evaluation. 'n'=participants who were evaluable at each specific time point for each arm.

ArmMeasureGroupValue (MEAN)Dispersion
OROS-MPH GroupStroop Color Word Naming TestTest 1: Baseline (n=128, 40)20.561 SecondsStandard Deviation 17.5433
OROS-MPH GroupStroop Color Word Naming TestTest 3: Baseline (n=128, 40)18.652 SecondsStandard Deviation 14.5219
OROS-MPH GroupStroop Color Word Naming TestTest 3: End of Week 12 (n=111, 40)16.946 SecondsStandard Deviation 12.1586
OROS-MPH GroupStroop Color Word Naming TestTest 2: Baseline (n=128, 40)19.32 SecondsStandard Deviation 14.8072
OROS-MPH GroupStroop Color Word Naming TestTest 4: Baseline (n=128, 40)22.868 SecondsStandard Deviation 11.3502
OROS-MPH GroupStroop Color Word Naming TestTest 1: End of Week 12 (n=111, 40)18.961 SecondsStandard Deviation 5.4474
OROS-MPH GroupStroop Color Word Naming TestTest 4: End of Week 12 (n=111, 40)19.388 SecondsStandard Deviation 9.8989
OROS-MPH GroupStroop Color Word Naming TestTest 2: End of Week 12 (n=111, 40)18.281 SecondsStandard Deviation 13.6981
Normal GroupStroop Color Word Naming TestTest 4: End of Week 12 (n=111, 40)10.488 SecondsStandard Deviation 4.2176
Normal GroupStroop Color Word Naming TestTest 1: Baseline (n=128, 40)6.213 SecondsStandard Deviation 2.3174
Normal GroupStroop Color Word Naming TestTest 1: End of Week 12 (n=111, 40)5.7 SecondsStandard Deviation 1.8355
Normal GroupStroop Color Word Naming TestTest 2: Baseline (n=128, 40)7.15 SecondsStandard Deviation 2.6341
Normal GroupStroop Color Word Naming TestTest 2: End of Week 12 (n=111, 40)6.675 SecondsStandard Deviation 2.2886
Normal GroupStroop Color Word Naming TestTest 3: End of Week 12 (n=111, 40)6.513 SecondsStandard Deviation 2.3898
Normal GroupStroop Color Word Naming TestTest 4: Baseline (n=128, 40)11.763 SecondsStandard Deviation 4.4202
Normal GroupStroop Color Word Naming TestTest 3: Baseline (n=128, 40)6.875 SecondsStandard Deviation 2.6451
Secondary

WCST: Completed Categories (Cc)

WCST is used to evaluate participants' abilities of abstract generalization, working memory, and distraction-cognitive clinically, which reflects participants' cognitive function objectively and comprehensively. WCST consists of 13 test indicators and all indicators will be analyzed separately. The 13 indicators are as follows: number of trials administered; number of categories completed; response corrects; percent corrects; total number of errors; trials to complete first category; percent conceptual level responses; perseverative responses; perseverative errors; percent perseverative errors; nonperseverative errors; failure to maintain set; learning to learn. In completed categoriies, number of categories completed out of 6 sorting categories after the test was evaluated. Ranges from 0 to 6. The more the number of categories completed the better is the response.

Time frame: Baseline and End of Week 12

Population: FAS population for OROS-MPH Group included participants who received at least 1 study drug and had at least one efficacy evaluation. FAS for normal group included all participants who had baseline scale evaluation and had at least one endpoint scale evaluation. n signifies participants who were evaluable at each time point for each specific arm.

ArmMeasureGroupValue (MEAN)Dispersion
OROS-MPH GroupWCST: Completed Categories (Cc)Baseline (n=128, 40)3.2 Nunber of Categories CompletedStandard Deviation 1.56
OROS-MPH GroupWCST: Completed Categories (Cc)End of Week 12 (n=111, 40)4.1 Nunber of Categories CompletedStandard Deviation 1.54
Normal GroupWCST: Completed Categories (Cc)Baseline (n=128, 40)3.3 Nunber of Categories CompletedStandard Deviation 1.68
Normal GroupWCST: Completed Categories (Cc)End of Week 12 (n=111, 40)4 Nunber of Categories CompletedStandard Deviation 1.34
Secondary

WCST: Correct Responses (Rc)

WCST is used to evaluate participants' abilities of abstract generalization, working memory, and distraction-cognitive clinically, which reflects participants' cognitive function objectively and comprehensively. WCST consists of 13 test indicators and all indicators will be analyzed separately. The 13 indicators are as follows: number of trials administered; number of categories completed; response corrects; percent corrects; total number of errors; trials to complete first category; percent conceptual level responses; perseverative responses; perseverative errors; percent perseverative errors; nonperseverative errors; failure to maintain set; learning to learn. The number of correct responses which meets all the requirements according to the response principles was evaluated. Ranges from 0-116, the more the better.

Time frame: Baseline and End of Week 12

Population: FAS population for OROS-MPH Group included participants who received at least 1 study drug and had at least one efficacy evaluation. FAS for normal group included all participants who had baseline scale evaluation and had at least one endpoint scale evaluation. n signifies participants who were evaluable at each time point for each specific arm.

ArmMeasureGroupValue (MEAN)Dispersion
OROS-MPH GroupWCST: Correct Responses (Rc)Baseline (n=128, 40)72.9 number of correct responsesStandard Deviation 15.65
OROS-MPH GroupWCST: Correct Responses (Rc)End of Week 12 (n=111, 40)80.3 number of correct responsesStandard Deviation 12.25
Normal GroupWCST: Correct Responses (Rc)Baseline (n=128, 40)77.9 number of correct responsesStandard Deviation 12.27
Normal GroupWCST: Correct Responses (Rc)End of Week 12 (n=111, 40)84.7 number of correct responsesStandard Deviation 12.3
Secondary

WCST: Error Responses (Re)

WCST is used to evaluate participants' abilities of abstract generalization, working memory, and distraction-cognitive clinically, which reflects participants' cognitive function objectively and comprehensively. WCST consists of 13 test indicators and all indicators will be analyzed separately. The 13 indicators are as follows: number of trials administered; number of categories completed; response corrects; percent corrects; total number of errors; trials to complete first category; percent conceptual level responses; perseverative responses; perseverative errors; percent perseverative errors; nonperseverative errors; failure to maintain set; learning to learn. Number of error responses which did not comply with the response principles was evaluated. Ranges from 0 to 128, the less the better.

Time frame: Baseline and End of Week 12

Population: FAS population for OROS-MPH Group included participants who received at least 1 study drug and had at least one efficacy evaluation. FAS for normal group included all participants who had baseline scale evaluation and had at least one endpoint scale evaluation. n signifies participants who were evaluable at each time point for each specific arm.

ArmMeasureGroupValue (MEAN)Dispersion
OROS-MPH GroupWCST: Error Responses (Re)Baseline (n=128, 40)52.3 number of error responsesStandard Deviation 18.59
OROS-MPH GroupWCST: Error Responses (Re)End of Week 12 (n= 111, 40)36.1 number of error responsesStandard Deviation 16.93
Normal GroupWCST: Error Responses (Re)Baseline (n=128, 40)42.9 number of error responsesStandard Deviation 17.77
Normal GroupWCST: Error Responses (Re)End of Week 12 (n= 111, 40)32.3 number of error responsesStandard Deviation 15.11
Secondary

WCST: Failure to Maintain Set (Fm)

WCST is used to evaluate participants' abilities of abstract generalization, working memory, and distraction-cognitive clinically, which reflects participants' cognitive function objectively and comprehensively. WCST consists of 13 test indicators and all indicators will be analyzed separately. The 13 indicators are as follows: number of trials administered; number of categories completed; response corrects; percent corrects; total number of errors; trials to complete first category; percent conceptual level responses; perseverative responses; perseverative errors; percent perseverative errors; nonperseverative errors; failure to maintain set; learning to learn. The frequency (number of times) of responses completed with 5 to 9 continuous correct was evaluated. Ranges from 0 to 26 and was not linear (cannot be considered to be good or bad just judged by the number, analyzed with other factors case by case).

Time frame: Baseline and End of Week 12

Population: FAS population for OROS-MPH Group included participants who received at least 1 study drug and had at least one efficacy evaluation. FAS for normal group included all participants who had baseline scale evaluation and had at least one endpoint scale evaluation. n signifies participants who were evaluable at each time point for each specific arm.

ArmMeasureGroupValue (MEAN)Dispersion
OROS-MPH GroupWCST: Failure to Maintain Set (Fm)Baseline (n=128, 40)1.7 number of timesStandard Deviation 1.62
OROS-MPH GroupWCST: Failure to Maintain Set (Fm)End of Week 12 (n=111, 40)2 number of timesStandard Deviation 1.78
Normal GroupWCST: Failure to Maintain Set (Fm)Baseline (n=128, 40)2.3 number of timesStandard Deviation 1.65
Normal GroupWCST: Failure to Maintain Set (Fm)End of Week 12 (n=111, 40)2.5 number of timesStandard Deviation 1.75
Secondary

WCST: First Response (Rf)

WCST is used to evaluate participants' abilities of abstract generalization, working memory, and distraction-cognitive clinically, which reflects participants' cognitive function objectively and comprehensively. WCST consists of 13 test indicators and all indicators will be analyzed separately. The 13 indicators are as follows: number of trials administered; number of categories completed; response corrects; percent corrects; total number of errors; trials to complete first category; percent conceptual level responses; perseverative responses; perseverative errors; percent perseverative errors; nonperseverative errors; failure to maintain set; learning to learn. Number of responses needed to complete the first color classification was evaluated. Ranges from 9 to 128, the lesser the better.

Time frame: Baseline and End of Week 12

Population: FAS population for OROS-MPH Group included participants who received at least 1 study drug and had at least one efficacy evaluation. FAS for normal group included all participants who had baseline scale evaluation and had at least one endpoint scale evaluation. n signifies participants who were evaluable at each time point for each specific arm.

ArmMeasureGroupValue (MEAN)Dispersion
OROS-MPH GroupWCST: First Response (Rf)Baseline (n=128,40)22.6 number of first responsesStandard Deviation 22.29
OROS-MPH GroupWCST: First Response (Rf)End of Week 12 (n=111, 40)23.4 number of first responsesStandard Deviation 19
Normal GroupWCST: First Response (Rf)Baseline (n=128,40)25.2 number of first responsesStandard Deviation 24.45
Normal GroupWCST: First Response (Rf)End of Week 12 (n=111, 40)26.5 number of first responsesStandard Deviation 22.77
Secondary

WCST: Learning to Learn (L-C)

WCST is used to evaluate participants' abilities of abstract generalization, working memory, and distraction-cognitive clinically, which reflects participants' cognitive function objectively and comprehensively. WCST consists of 13 test indicators and all indicators will be analyzed separately. Learning to learn indicator was a measure of decrement in the number of responses needed to achieve each successive category. The raw score ranged from 0 to 100. The high, negative value suggests the participants could not effectively learn the task presented by the WCST. Only calculated in those completed 3 or more categories and not linear (cannot be considered to be good or bad just judged by the number, analyzed with other factors case by case).

Time frame: Baseline and End of Week 12

Population: FAS population for OROS-MPH Group included participants who received at least 1 study drug and had at least one efficacy evaluation. FAS for normal group included all participants who had baseline scale evaluation and had at least one endpoint scale evaluation. n signifies participants who were evaluable at each time point for each specific arm.

ArmMeasureGroupValue (MEAN)Dispersion
OROS-MPH GroupWCST: Learning to Learn (L-C)Baseline (n=128, 40)-2.49 number of responsesStandard Deviation 6.451
OROS-MPH GroupWCST: Learning to Learn (L-C)End of Week 12 (n=111, 40)-1.87 number of responsesStandard Deviation 3.85
Normal GroupWCST: Learning to Learn (L-C)Baseline (n=128, 40)-2.37 number of responsesStandard Deviation 6.31
Normal GroupWCST: Learning to Learn (L-C)End of Week 12 (n=111, 40)-1.34 number of responsesStandard Deviation 4.391
Secondary

WCST: Non-Persistent Error Responses (nRpe)

WCST is used to evaluate participants' abilities of abstract generalization, working memory, and distraction-cognitive clinically, which reflects participants' cognitive function objectively and comprehensively. WCST consists of 13 test indicators and all indicators will be analyzed separately. The 13 indicators are as follows: number of trials administered; number of categories completed; response corrects; percent corrects; total number of errors; trials to complete first category; percent conceptual level responses; perseverative responses; perseverative errors; percent perseverative errors; nonperseverative errors; failure to maintain set; learning to learn. Non perseverative error responses are the errors remaining after subtracting persistent errors from total errors. Ranges from 0 to 128 and was not linear (cannot be considered to be good or bad just judged by the number, analyzed with other factors case by case).

Time frame: Baseline and End of Week 12

Population: FAS population for OROS-MPH Group included participants who received at least 1 study drug and had at least one efficacy evaluation. FAS for normal group included all participants who had baseline scale evaluation and had at least one endpoint scale evaluation. n signifies participants who were evaluable at each time point for each specific arm.

ArmMeasureGroupValue (MEAN)Dispersion
OROS-MPH GroupWCST: Non-Persistent Error Responses (nRpe)Baseline (n=128, 40)23.54 number of non-persistent error responsesStandard Deviation 11.606
OROS-MPH GroupWCST: Non-Persistent Error Responses (nRpe)End of Week 12 (n=111, 40)16.75 number of non-persistent error responsesStandard Deviation 9.241
Normal GroupWCST: Non-Persistent Error Responses (nRpe)Baseline (n=128, 40)19.98 number of non-persistent error responsesStandard Deviation 8.94
Normal GroupWCST: Non-Persistent Error Responses (nRpe)End of Week 12 (n=111, 40)15.8 number of non-persistent error responsesStandard Deviation 7.737
Secondary

WCST: Percentage of Conceptual Level Responses (Rf%)

WCST is used to evaluate participants' abilities of abstract generalization, working memory, and distraction-cognitive clinically, which reflects participants' cognitive function objectively and comprehensively. WCST consists of 13 test indicators and all indicators will be analyzed separately. The 13 indicators are as follows: number of trials administered; number of categories completed; response corrects; percent corrects; total number of errors; trials to complete first category; percent conceptual level responses; perseverative responses; perseverative errors; percent perseverative errors; nonperseverative errors; failure to maintain set; learning to learn. Percentage of the responses completed with 3-10 continuous correct during the entire measuring process was evaluated. Ranges from 0 to 100%, the more the better.

Time frame: Baseline and End of Week 12

Population: FAS population for OROS-MPH Group included participants who received at least 1 study drug and had at least one efficacy evaluation. FAS for normal group included all participants who had baseline scale evaluation and had at least one endpoint scale evaluation. n signifies participants who were evaluable at each time point for each specific arm.

ArmMeasureGroupValue (MEAN)Dispersion
OROS-MPH GroupWCST: Percentage of Conceptual Level Responses (Rf%)Baseline (n=128, 40)46.36 percentage of conceptual level responsesStandard Deviation 18.589
OROS-MPH GroupWCST: Percentage of Conceptual Level Responses (Rf%)End of Week 12 (n=111, 40)61.07 percentage of conceptual level responsesStandard Deviation 17.244
Normal GroupWCST: Percentage of Conceptual Level Responses (Rf%)Baseline (n=128, 40)54.73 percentage of conceptual level responsesStandard Deviation 18.48
Normal GroupWCST: Percentage of Conceptual Level Responses (Rf%)End of Week 12 (n=111, 40)65 percentage of conceptual level responsesStandard Deviation 16.036
Secondary

WCST: Percentage of Correct Responses (Rc%)

WCST is used to evaluate participants' abilities of abstract generalization, working memory, and distraction-cognitive clinically, which reflects participants' cognitive function objectively and comprehensively. WCST consists of 13 test indicators and all indicators will be analyzed separately. The 13 indicators are as follows: number of trials administered; number of categories completed; response corrects; percent corrects; total number of errors; trials to complete first category; percent conceptual level responses; perseverative responses; perseverative errors; percent perseverative errors; nonperseverative errors; failure to maintain set; learning to learn. Percentage of correct responses which meets all the requirements according to the response principles was evaluated. Ranges from 0 to 100 percent (%), the more the better.

Time frame: Baseline and End of Week 12

Population: FAS population for OROS-MPH Group included participants who received at least 1 study drug and had at least one efficacy evaluation. FAS for normal group included all participants who had baseline scale evaluation and had at least one endpoint scale evaluation. n signifies participants who were evaluable at each time point for each specific arm.

ArmMeasureGroupValue (MEAN)Dispersion
OROS-MPH GroupWCST: Percentage of Correct Responses (Rc%)Baseline (n=128, 40)58.678 Percentage of correct responsesStandard Deviation 13.8072
OROS-MPH GroupWCST: Percentage of Correct Responses (Rc%)End of Week 12 (n=111, 40)70.096 Percentage of correct responsesStandard Deviation 11.6311
Normal GroupWCST: Percentage of Correct Responses (Rc%)Baseline (n=128, 40)65.52 Percentage of correct responsesStandard Deviation 12.6227
Normal GroupWCST: Percentage of Correct Responses (Rc%)End of Week 12 (n=111, 40)73.34 Percentage of correct responsesStandard Deviation 10.5072
Secondary

WCST: Percentage of Perseverative Error Responses (Rpe%)

WCST is used to evaluate participants' abilities of abstract generalization, working memory, and distraction-cognitive clinically, which reflects participants' cognitive function objectively and comprehensively. WCST consists of 13 test indicators and all indicators will be analyzed separately. The 13 indicators are as follows: number of trials administered; number of categories completed; response corrects; percent corrects; total number of errors; trials to complete first category; percent conceptual level responses; perseverative responses; perseverative errors; percent perseverative (pvt) errors; nonperseverative errors; failure to maintain set; learning to learn. Percentage of persistent errors out of total number of responses was evaluated. Ranges from 0 to 100%, the less the better.

Time frame: Baseline and End of Week 12

Population: FAS population for OROS-MPH Group included participants who received at least 1 study drug and had at least one efficacy evaluation. FAS for normal group included all participants who had baseline scale evaluation and had at least one endpoint scale evaluation. n signifies participants who were evaluable at each time point for each specific arm.

ArmMeasureGroupValue (MEAN)Dispersion
OROS-MPH GroupWCST: Percentage of Perseverative Error Responses (Rpe%)Baseline (n=128, 40)22.67 Percentage of pvt error responsesStandard Deviation 11.658
OROS-MPH GroupWCST: Percentage of Perseverative Error Responses (Rpe%)End of Week 12 (n=111, 40)16.07 Percentage of pvt error responsesStandard Deviation 9.188
Normal GroupWCST: Percentage of Perseverative Error Responses (Rpe%)Baseline (n=128, 40)18.45 Percentage of pvt error responsesStandard Deviation 8.083
Normal GroupWCST: Percentage of Perseverative Error Responses (Rpe%)End of Week 12 (n=111, 40)13.59 Percentage of pvt error responsesStandard Deviation 7.167
Secondary

WCST: Perseverative Error Responses (Rpe)

WCST is used to evaluate participants' abilities of abstract generalization, working memory, and distraction-cognitive clinically, which reflects participants' cognitive function objectively and comprehensively. WCST consists of 13 test indicators and all indicators will be analyzed separately. The 13 indicators are as follows: number of trials administered; number of categories completed; response corrects; percent corrects; total number of errors; trials to complete first category; percent conceptual level responses; perseverative responses; perseverative errors; percent perseverative errors; nonperseverative errors; failure to maintain set; learning to learn. Perseverative error responses are the number of responses which applied continuity principle for matching answers and also had the wrong answer was evaluated. Ranges from 0 to 128, the less the better.

Time frame: Baseline and End of Week 12

Population: FAS population for OROS-MPH Group included participants who received at least 1 study drug and had at least one efficacy evaluation. FAS for normal group included all participants who had baseline scale evaluation and had at least one endpoint scale evaluation. n signifies participants who were evaluable at each time point for each specific arm.

ArmMeasureGroupValue (MEAN)Dispersion
OROS-MPH GroupWCST: Perseverative Error Responses (Rpe)Baseline (n=128, 40)28.7 number of perseverative error responsesStandard Deviation 15.24
OROS-MPH GroupWCST: Perseverative Error Responses (Rpe)End of Week 12 (n=111, 40)19.4 number of perseverative error responsesStandard Deviation 12.54
Normal GroupWCST: Perseverative Error Responses (Rpe)Baseline (n=128, 40)23 number of perseverative error responsesStandard Deviation 11.03
Normal GroupWCST: Perseverative Error Responses (Rpe)End of Week 12 (n=111, 40)16.4 number of perseverative error responsesStandard Deviation 9.85
Secondary

WCST: Perseverative Responses (Rp)

WCST is used to evaluate participants' abilities of abstract generalization, working memory, and distraction-cognitive clinically, which reflects participants' cognitive function objectively and comprehensively. WCST consists of 13 test indicators and all indicators will be analyzed separately. The 13 indicators are as follows: number of trials administered; number of categories completed; response corrects; percent corrects; total number of errors; trials to complete first category; percent conceptual level responses; perseverative responses; perseverative errors; percent perseverative errors; nonperseverative errors; failure to maintain set; learning to learn. Number of perseverative responses were the responses which applied continuity principle for matching answers was evaluated. Ranges from 0 to 100, the less the better.

Time frame: Baseline and End of Week 12

Population: FAS population for OROS-MPH Group included participants who received at least 1 study drug and had at least one efficacy evaluation. FAS for normal group included all participants who had baseline scale evaluation and had at least one endpoint scale evaluation. n signifies participants who were evaluable at each time point for each specific arm.

ArmMeasureGroupValue (MEAN)Dispersion
OROS-MPH GroupWCST: Perseverative Responses (Rp)Baseline (n=128, 40)33.7 number of perseverative responsesStandard Deviation 20.47
OROS-MPH GroupWCST: Perseverative Responses (Rp)End of Week 12 (n=111, 40)22 number of perseverative responsesStandard Deviation 16.21
Normal GroupWCST: Perseverative Responses (Rp)Baseline (n=128, 40)26.5 number of perseverative responsesStandard Deviation 14.09
Normal GroupWCST: Perseverative Responses (Rp)End of Week 12 (n=111, 40)18.6 number of perseverative responsesStandard Deviation 12.97
Secondary

Wisconsin Card Sorting Test (WCST): Administered Responses (Ra) of Completed Examination

WCST is used to evaluate participants' abilities of abstract generalization, working memory, and distraction-cognitive clinically, which reflects participants' cognitive function objectively and comprehensively. WCST consists of 13 test indicators and all indicators will be analyzed separately. The 13 indicators are as follows: number of trials administered; number of categories completed; response corrects; percent corrects; total number of errors; trials to complete first category; percent conceptual level responses; perseverative responses; perseverative errors; percent perseverative errors; nonperseverative errors; failure to maintain set; learning to learn. During number of trials administered or administered responses, participants were administered 128 cards and asked to sort the cards until all the 6 sorting categories was completed. Response number used to complete all 6 categories ranges from 50 to 128, lesser the better.

Time frame: Baseline and End of Week 12

Population: FAS population for OROS-MPH Group included participants who received at least 1 study drug and had at least one efficacy evaluation. FAS for normal group included all participants who had baseline scale evaluation and had at least one endpoint scale evaluation. n signifies participants who were evaluable at each time point for each specific arm.

ArmMeasureGroupValue (MEAN)Dispersion
OROS-MPH GroupWisconsin Card Sorting Test (WCST): Administered Responses (Ra) of Completed ExaminationBaseline (n=128, 40)125.1 ResponsesStandard Deviation 8.74
OROS-MPH GroupWisconsin Card Sorting Test (WCST): Administered Responses (Ra) of Completed ExaminationEnd of Week 12 (n=111, 40)116.4 ResponsesStandard Deviation 17.68
Normal GroupWisconsin Card Sorting Test (WCST): Administered Responses (Ra) of Completed ExaminationBaseline (n=128, 40)120.8 ResponsesStandard Deviation 5.53
Normal GroupWisconsin Card Sorting Test (WCST): Administered Responses (Ra) of Completed ExaminationEnd of Week 12 (n=111, 40)117.1 ResponsesStandard Deviation 17.37

Source: ClinicalTrials.gov · Data processed: Mar 3, 2026